A single institution experience of extranodal natural killer/T cell lymphoma of nasal type

References

• Au WY, Gascoyne RD, Klasa RD, et al. Incidence and spectrum of non-Hodgkin lymphoma in Chinese migrants to British Columbia. Br J Haematol 2005;128:792–796.
   PubMed Web of Science ®Google Scholar
• Au WY. Current management of nasal NK/T-cell lymphoma. Oncology (Williston Park) 2010;24:352–358.
   PubMed Web of Science ®Google Scholar
• Savage KJ. Prognosis and primary therapy in peripheral T-cell lymphomas. Hematology Am Soc Hematol Educ Program 2008;280–288.
   PubMedGoogle Scholar
• Huang M-J, Jiang Y, Liu W-P, et al. Early or up-front radiotherapy improved survival of localized extranodal NK/T-cell lymphoma, nasal-type in the upper aerodigestive tract. Int J Radiat Oncol Biol Phys 2008;70:166–174.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Kita K, Miwa H, et al. Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer 1995;76:2351–2356.
   PubMed Web of Science ®Google Scholar
• Drénou B, Lamy T, Amiot L, et al. CD3- CD56 + non-Hodgkin's lymphomas with an aggressive behavior related to multidrug resistance. Blood 1997;89:2966–2974.
   PubMed Web of Science ®Google Scholar
• Huang H, Lin Z, Lin X, et al. Long-term outcomes of patients with newly diagnosed extranodal natural killer/T-cell lymphoma treated by etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin regimen: a single-institution experience. Leuk Lymphoma 2011;52:1041–1048.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Kwong Y-L, Kim WS, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol 2011;29: 4410–4416.
   PubMed Web of Science ®Google Scholar
• Peh SC. Host ethnicity influences non-Hodgkin's lymphoma subtype frequency and Epstein-Barr virus association rate: the experience of a multi-ethnic patient population in Malaysia. Histopathology 2001;38:458–465.
   PubMed Web of Science ®Google Scholar
• Xu J-X, Hoshida Y, Yang W-I, et al. Life-style and environmental factors in the development of nasal NK/T-cell lymphoma: a case-control study in East Asia. Int J Cancer 2007;120:406–410.
   PubMed Web of Science ®Google Scholar
• Pagano L, Gallamini A, Trapè G, et al. NK/T-cell lymphomas “nasal type”: an Italian multicentric retrospective survey. Ann Oncol 2006;17:794–800.
   PubMed Web of Science ®Google Scholar
• Ai WZ, Chang ET, Fish K, et al. Racial patterns of extranodal natural killer/T-cell lymphoma, nasal type, in California: a population-based study. Br J Haematol 2012;156:626–632.
   PubMed Web of Science ®Google Scholar
• William BM, Armitage JO. International analysis of the frequency and outcomes of NK/T-cell lymphomas. Best Pract Res Clin Haematol 2013;26:23–32.
   PubMed Web of Science ®Google Scholar
• Koom WS, Chung EJ, Yang W-I, et al. Angiocentric T-cell and NK/T-cell lymphomas: radiotherapeutic viewpoints. Int J Radiat Oncol Biol Phys 2004;59:1127–1137.
   PubMed Web of Science ®Google Scholar
• Sakata K, Fuwa N, Kodaira T, et al. Analyses of dose-response in radiotherapy for patients with mature T/NK-cell lymphomas according to the WHO classification. Radiother Oncol 2006;79:179–184.
   PubMed Web of Science ®Google Scholar
• Kim S, Kim K, Kim B, et al. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-cell lymphoma: Consortium for Improving Survival of Lymphoma study. J Clin Oncol 2009;27:6027–3217.
   PubMed Web of Science ®Google Scholar
• Wang H, Li Y, Wang WH, et al. Mild toxicity and favorable prognosis of high-dose and extended involved-field intensity-modulated radiotherapy for patients with early-stage nasal NK/T-cell lymphoma. Int J Radiat Oncol Biol Phys 2012;82:1115–1121.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Kita K, Miwa H, et al. Frequent expression of P-glycoprotein/MDR1 by nasal T cell lymphoma cells. Cancer 1995;76:2351–2356.
   PubMed Web of Science ®Google Scholar
• Nagafuji K, Fujisaki T, Arima F, et al. L-asparginase induced durable remission of relapsed NK/T cell lymphoma after autolgous peripheral blood stem cell transplantation. Int J Hematol 2001;74:447–450.
   PubMed Web of Science ®Google Scholar
• Matsumoto Y, Nomura K, Kanda-Akano Y, et al. Successful treatment with Ervenia L-asparginase for recurrent natural -killer/ T cell lymphoma. Leuk Lymphoma 2003;44:879–882.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Suzuki R, Kwong YL, et al. Phase 1 study of dexamethasone, methotrexate, ifosfamide, L-asparginase and etoposide (SMILE) chemotherapy for advanced stage, relapsed or refractory extranodal natural killer (NK)/T cell lymphoma and leukemia. Cancer Sci 2008;99:1016–1020.
   PubMed Web of Science ®Google Scholar